Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open, Dose Escalation/Dose Exploration, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single/Multiple Infusion of CT0180 Injection in Patients With Advanced Hepatocellular Carcinoma

Next Previous
X
Search
Trial Profile

An Open, Dose Escalation/Dose Exploration, Phase I Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Single/Multiple Infusion of CT0180 Injection in Patients With Advanced Hepatocellular Carcinoma

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 19 Jul 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs GPC3-CAR-T (Primary) ; Cyclophosphamide; Fludarabine
  • Indications Liver cancer
  • Focus Adverse reactions

    • Most Recent Events

    • 14 Jul 2023 Planned End Date changed from 30 Apr 2023 to 1 Jun 2024.
    • 14 Jul 2023 Planned primary completion date changed from 30 Mar 2023 to 1 Jun 2024.
    • 06 Jun 2023 Results (n=7) assessing safety and efficacy of CT0180 in patients with advanced hepatocellular carcinoma presented at the 59th Annual Meeting of the American Society of Clinical Oncology

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top